Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.
Despite the turbulence of the past few years—pandemic, geopolitical conflict, inflation—climate change remains a top issue for technology, media, and telecommunications (TMT) companies. In fact, ...
1] VMS TMT IPO GMP today: Market observers say the company's shares are available at a premium of ₹24 in the grey market today. 3] VMS TMT IPO date: The book build issue opened on 17 September 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results